Screener
Haemonetics HAE Income Statement
| Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | ||
|---|---|---|---|---|---|---|
| $339.38M+5.6% | $346.35M+4.8% | $338.97M-2.7% | $327.32M-5.3% | $321.39M-4.4% | ||
| $136.58M+5.8% | $148.14M+7.7% | $136.58M-11.9% | $132.57M-16.1% | $129.15M-19.9% | ||
| $202.8M+5.5% | $198.21M+2.7% | $202.39M+4.6% | $194.74M+3.9% | $192.24M+9.9% | ||
| 59.8%-0.1pp | 57.2%-1.2pp | 59.7%+4.2pp | 59.5%+5.2pp | 59.8%+7.8pp | ||
| $16.2M-0.4% | $14.45M-21.1% | $14.19M-10.4% | $14.87M+5.2% | $16.26M+12.5% | ||
| $118.94M+7.4% | $120.93M+5.0% | $109.15M+2.5% | $101.62M-5.0% | $110.72M+2.3% | ||
| $145.35M+5.0% | $221.24M+81.8% | $134.99M+0.4% | $136.25M+0.4% | $138.37M+2.4% | ||
| $57.46M+6.7% | —— | $67.4M+14.2% | $58.49M+13.1% | $53.87M+35.5% | ||
| 16.9%+0.2pp | —— | 19.9%+2.9pp | 17.9%+2.9pp | 16.8%+4.9pp | ||
| -$9.88M-13.6% | -$5.37M-799% | -$7.42M+18.6% | -$7.21M-3.0% | -$8.7M-225% | ||
| $47.57M+5.3% | —— | $59.98M+20.1% | $51.29M+14.7% | $45.17M-3.3% | ||
| $14.56M+30.8% | —— | $15.24M+22.6% | $12.6M+15.9% | $11.14M+33.5% | ||
| $33.01M-3.0% | —— | $44.74M+19.3% | $38.68M+14.3% | $34.03M-11.3% | ||
| 9.7%-0.9pp | —— | 13.2%+2.4pp | 11.8%+2.0pp | 10.6%-0.8pp | ||
| $0.72+2.9% | —— | $0.95+28.4% | $0.81+22.7% | $0.70-5.4% | ||
| $84.57M+2.3% | —— | $94.78M+7.6% | $86.75M+7.2% | $82.63M+19.9% | ||
| 24.9%-0.8pp | —— | 28%+2.7pp | 26.5%+3.1pp | 25.7%+5.2pp | ||
| $57.46M+6.7% | —— | $67.4M+14.2% | $58.49M+13.1% | $53.87M+35.5% |
FAQ
- What is Haemonetics's revenue?
- Haemonetics (HAE) generated $1.4B in revenue over the trailing twelve months, up 0.4% year over year.
- Is Haemonetics profitable?
- Haemonetics reported $150.5M in net income over the trailing twelve months, a 13.3% net margin.
- What are Haemonetics's profit margins?
- Gross margin is 59.0% and operating margin is 19.0%, with a 13.3% net margin.
- What is Haemonetics's earnings per share?
- Haemonetics's diluted EPS over the trailing twelve months is $3.18.
- Where does Haemonetics's income statement data come from?
- Every line is extracted from Haemonetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
